Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

PURPOSE: Abiraterone is the active metabolite of the pro-drug abiraterone acetate (AA) and a selective inhibitor of CYP17, a key enzyme in testosterone synthesis, and improves overall survival in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC). This open-label, single-arm phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolcher, A. W., Chi, K. N., Shore, N. D., Pili, R., Molina, A., Acharya, M., Kheoh, T., Jiao, J. J., Gonzalez, M., Trinh, A., Pankras, C., Tran, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405235/
https://www.ncbi.nlm.nih.gov/pubmed/22752297
http://dx.doi.org/10.1007/s00280-012-1916-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405235/
https://www.ncbi.nlm.nih.gov/pubmed/22752297
http://dx.doi.org/10.1007/s00280-012-1916-9

Ejemplares similares